Strong sales growth and a tripling of EBIT drive optimism, though geopolitical tensions and a medical division decline pose challenges.

Drägerwerk AG & Co. KGaA (ETR:DRW3) reported higher sales, sharply improved earnings and a return to positive free cash flow in the first half of 2026, supported by demand across its safety business, improved gross margins and customs refunds recognized during the second quarter. Chief Executiv

Drägerwerk AG & Co. KGaA (ETR:DRW3) reported higher order intake, revenue growth, and a sharp improvement in earnings in the first quarter of 2026, supported by strong demand in its medical business and improving profitability in its safety division. CEO Stefan Dräger described the period as “a

Draegerwerk AG & Co KGaA (DGWPF) reports historic net sales and robust EBIT growth, while navigating currency headwinds and rising expenses.

Drägerwerk KGaA (XTRA:DRW3) has caught investor attention after a period of strong longer term share performance, with total return figures over the past year and past 3 months standing out compared with its recent monthly moves. See our latest analysis for Drägerwerk KGaA. At a share price of €90.0, Drägerwerk KGaA’s recent 3.93% 1 day and 31.77% 90 day share price returns sit alongside a 68.56% 1 year total shareholder return. This suggests that momentum has been building rather than...

Deciding what to do with Drägerwerk KGaA stock? You are certainly not alone. After all, the company’s share price has been on a remarkable journey lately, jumping by 49.2% so far this year and notching up an impressive 53.9% gain over the past twelve months. Even in just the last week, shares edged up 0.9%. While the ride has not always been smooth—returns over the past month held steady and the five-year gain sits at 8.2%—these numbers hint at renewed market optimism and changing attitudes...